Rethinking Youth Gender Medicine with Dr Louise Irvine
Stella O'Malley and her co-hosts speak with Dr Louise Irvine, a UK GP and Co-Chair of CAN-SG, about the state of youth gender medicine in Britain — and what Ireland urgently needs to take from it. The conversation covers institutional capture of the NHS, the WellBN investigation, a landmark clinical conference and the long-overdue call for honest evidence. For Irish parents, clinicians and policymakers, the parallels are impossible to ignore.
Dr Louise Irvine is a practising General Practitioner, GP trainer and Co-Chair of the Clinical Advisory Network on Sex and Gender — known as CAN-SG. In this episode she joins Stella O'Malley and her co-hosts to map the state of youth gender medicine in Britain: how it developed, where it went wrong, and what a responsible clinical path forward might look like. The conversation is wide-ranging, covering aetiology, research, ethics and the day-to-day realities facing practitioners who have dared to raise questions about the direction of their field. Much of the episode centres on CAN-SG's conference, "Rethinking Youth Gender Medicine," held in London in early July 2026. The conference brought together clinicians, researchers and policy experts to examine how institutions ended up here — and what genuine, evidence-based care for young people with gender distress should look like. For any Irish doctor, nurse, therapist or school counsellor who has felt isolated in their clinical scepticism, the fact that a professional body is now hosting this conversation openly and at scale matters enormously. Dr Irvine recounts the findings of the WellBN investigation, a recent inquiry into a UK gender clinic that has added to growing concerns about standards of care. She and Stella explore how the NHS — and the broader clinical establishment — became captured by an ideology that treated gender-affirming pathways as beyond scrutiny. It is a story of institutional groupthink, silenced dissent and a generation of patients whose long-term outcomes were never systematically tracked. Ireland has not been immune to similar pressures. Irish clinicians have operated in a climate where questioning the dominant gender-affirming framework could invite professional censure. The policy debate here has lagged well behind the clinical reckoning now under way in the UK. As Stella O'Malley has explored across many episodes, the psychotherapeutic needs of young people with gender distress are complex — and rarely served well by a fast-tracked medical route that skips careful psychological assessment. The episode also takes on what Helen Joyce has called "tooth fairy science" — research that was treated as settled and authoritative but which, on close inspection, cannot bear the weight placed on it. The puberty blocker trial is examined alongside the wider question of what evidence is still missing: proper data linkage, long-term follow-up and studies that track real outcomes for real patients over time. These are not fringe demands. They are the basic requirements of ethical medicine, and Ireland's evolving approach to this area will need to grapple with exactly these questions. For Irish parents trying to make sense of what their child's distress means, for GPs fielding referral requests without adequate guidance, and for policymakers shaping what youth services will exist here, this conversation is a grounding resource. The UK is several steps ahead in its reckoning — and listening carefully to clinicians like Dr Louise Irvine is one of the fastest ways for Ireland to learn without repeating the same costly mistakes.
